Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: E'Lane who wrote (8840)	6/1/1998 3:23:00 PM
From: Frostman	Respond to of 23519

"VeVus and Vutthead" LOL! maybe they can scratch together a reasonable corporate press release from this article. The stock has slipped to under $9 a share. ************************************************************ <<06/01 12:30 New impotence drug helps two-thirds of men - study LONDON, June 1 (Reuters) - A European trial of a new treatment for impotence has shown it is effective in two-thirds of men, doctors said on Monday. Gordon Williams, a urologist at Hammersmith Hospital in London who co-ordinated the trial of MUSE in 13 clinics in England, France, Germany, Ireland and the Netherlands, found it helped 69 percent of the 159 men who received it achieve intercourse. "Many other studies use a firm erection as a successful end-point. However, we used sexual intercourse as it is the best end-point to determine the efficacy of treatments for erectile dysfunction (impotence)," Williams said in a statement. The European study, published in the British Journal of Urology, showed that MUSE was effective both in the short and long term for men who suffered from impotence of a physical origin. Unlike the best-selling Viagra impotence pill which has enhanced the performance of thousands of American men, MUSE comes with an applicator that is inserted into the tip of the penis. It releases a pellet with a specified dose of the drug alprostadil that causes an erection within five to 10 minutes and lasting for up to an hour. A total of 763 doses of MUSE, made by U.S. drug-maker VIVUS Inc, were administered during the trial and 51 percent resulted in sexual intercourse. Nearly 250 patients were treated as outpatients and 64 percent had intercourse. The successful patients were randomised to receive either MUSE or a placebo during a self-administered three-month trial at home. Nearly 70 percent of MUSE patients reported success, compared to 11 percent in the control group. All the patients recorded their reaction to the treatment, levels of discomfort and any adverse reactions. "Side-effects with MUSE were all local and minor, with mild penile pain reported in just four percent of patients," said Williams. He added that MUSE is effective in patients suffering from physical and psychologically caused impotence and patients who have had surgery for prostate cancer. Because it is a local treatment there is no danger of systemic side-effects, or reaction in other parts of the body. MUSE is cleared for commercial distribution in the United States and Britain and is expected to be launched in South Africa at the end of the summer. The U.S. Food and Drug Administration and Pfizer, the makers of Viagra, are investigating the deaths of six men who died while taking the impotence pill. It is not clear if any of the deaths were caused by the drug. Impotence is a widespread problem that affects 10 percent of men world-wide. It is more common in older men and those who have high blood pressure, diabetes and neurological disorders or who have had surgery for prostate cancer.>> EOM